(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






1735 Result: Health

Novartis receives FDA approval for expanded use of Zykadia(R) in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)

May 26th, 2017

* In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] * The overall intracranial response rate in patients with measurable brain metastases was 57% . Read more

Barrick Comments on Potential Impact of Tanzania Concentrate Export Ban

May 25th, 2017

All amounts expressed in U.S. dollars Toronto, Ontario / CRWE PRESS RELEASE / May 25, 2017 -  Barrick Gold Corporation (NYSE:ABX)(TSX:ABX) (“Barrick” or the “Company”) today commented on the potential impact of an. Read more

Nature's Sunshine Products Receives Direct Selling License in China

May 16th, 2017

LEHI, Utah / CRWE PRESS RELEASE / May 16, 2017 - Nature’s Sunshine Products (NASDAQ: NATR), “the Company”, a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal . Read more

Dow Announces Next Phase of Comprehensive Investments to Deliver Long-Term Competitive Advantage and Earnings Growth

May 11th, 2017

* Additional projects extend U.S. growth investments to more than $12 billion over 10-year period * Fuels domestic job creation and economic activity; multiplier effect leads to ~2,000 new, high-skilled U.S. jobs tied to state-of-the-art manufacturi. Read more

Merus Labs and Norgine Enter into a Definitive Arrangement Agreement

May 11th, 2017

* Norgine to acquire all outstanding shares of Merus for $1.65 per share in cash TORONTO, ONTARIO and AMSTERDAM, NETHERLANDS / CRWE PRESS RELEASE / May 11 , 2017 - Merus Labs International Inc. ("Merus" or the "Company") TSX: MSL, NASDAQ: MSLI and. Read more

Astrotech Subsidiary 1st Detect to Pursue Strategic Alternatives

May 10th, 2017

Austin, TX / CRWE PRESS RELEASE / May 10, 2017 - Astrotech Corporation’s (NASDAQ: ASTC) board of directors and management announce that they have engaged Chardan to advise on strategic alternatives involving Astrotech subsidiary 1st Detect Corp. Read more

Inpixon Announces Purchase Order From Leading Health Insurer

May 08th, 2017

PALO ALTO, Calif. / CRWE PRESS RELEASE / May 8, 2017 - Inpixon (NASDAQ: INPX), a leading indoor positioning and data analytics company, announced today it received a purchase order of approximately $2.5 million from a leading Fortune 500 health . Read more

Bovie Medical Receives 510K Clearance for its J-Plasma(R) Precise Flex Handpiece

May 08th, 2017

The Addition of the J-Plasma® Precise Flex rounds out Bovie Medical’s J-Plasma® offering to include products designed for open and minimally invasive surgical procedures, including laparoscopic and robotic approaches. CLEARWATER, FL . Read more

VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study

May 02nd, 2017

Cambridge, Massachusetts / CRWE PRESS RELEASE / May 2, 2017 - VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today provided an update on its cytomegalovirus (“CMV”) Phase I clinical study, which is assessing the safety an. Read more

Infosys to Hire 10,000 American Workers Over the Next Two Years and Establish Four Technology and Innovation Hubs in the United States

May 02nd, 2017

Indianapolis, Indiana / CRWE PRESS RELEASE / May 2, 2017 - Infosys (NYSE: INFY), a global leader in consulting, technology and next-generation services, today announced that it plans to hire 10,000 American workers over the next two years. As part of. Read more

Kitov Pharmaceuticals Files 6-K with Update on Israeli Securities Authority Investigation

May 01st, 2017

TEL AVIV, Israel / CRWE PRESS RELEASE / May 1, 2017 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, today filed a 6-K with an update on the ongoing Israeli Securities Authority Investigation.. Read more

Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI(R)

April 25th, 2017

• Servier will commercialize PIXUVRI in all markets except the US • CTI BioPharma will retain rights to commercialize PIXUVRI in the US Paris, France and Seattle, Washington / CRWE PRESS RELEASE / April 25, 2017 – Servier and CTI . Read more

Cancer Genetics, Inc. Launches a Unique, Industry-Leading Panel That Provides Comprehensive & Precise Information for Immuno-Oncology Therapy Assessment & Patient Monitoring

April 24th, 2017

* Complete::IO™ provides immune endpoint and immune monitoring of patients allowing informed therapeutic decisions and assessment of potential toxicities of IO therapies in blood cancers and solid tumors * Complete::IO™ can determine pre. Read more

CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial

April 20th, 2017

Bedminster, NJ / CRWE PRESS RELEASE / April 20, 2017 - CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,. Read more

Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine

April 18th, 2017

- Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology - - Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development - - Existing Investors OrbiMed Advisors. Read more

Load More Content